1. Libby, P. Inflammation in atherosclerosis. Nature 2002, 420, 868–874. [CrossRef] [PubMed]
2. Shimada, H.; Rajagopalan, L.E. Rho kinase-2 activation in human endothelial cells driveslysophosphatidic acid-mediated expression of cell adhesion molecules via NF-kappaB p65. J. Biol. Chem. 2010, 285, 12536–12542. [CrossRef] [PubMed]
3. Zhao, Y.; Tong, J.; He, D.; Pendyala, S.; Evgeny, B.; Chun, J.; Sperling, A.I.; Natarajan, V. Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma. Respir. Res. 2009, 10, 114. [CrossRef] [PubMed]
4. Dohi, T.; Miyauchi, K.; Ohkawa, R.; Nakamura, K.; Kishimoto, T.; Miyazaki, T.; Nishino, A.; Nakajima, N.; Yaginuma, K.; Tamura, H.; et al. Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. Clin. Chim. Acta 2012, 413, 207–212. [CrossRef] [PubMed]
5. Li, H.Y.; Oh, Y.S.; Choi, J.W.; Jung, J.Y.; Jun, H.S. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice. Kidney Int. 2017, 91, 1362–1373. [CrossRef] [PubMed]
6. Siess, W.; Zangl, K.J.; Essler, M.; Bauer, M.; Brandl, R.; Corrinth, C.; Bittman, R.; Tigyi, G.; Aepfelbacher, M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 1999, 96, 6931–6936. [CrossRef] [PubMed]
7. Bot, M.; Bot, I.; Lopez-Vales, R.; van de Lest, C.H.; Saulnier-Blache, J.S.; Helms, J.B.; David, S.; van Berkel, T.J.; Biessen, E.A. Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation. Am. J. Pathol. 2010, 176, 3073–3084. [CrossRef]
8. Schober, A.; Siess, W. Lysophosphatidic acid in atherosclerotic diseases. Br. J. Pharmacol. 2012, 167, 465–482. [CrossRef]
9. Zhou, Z.; Subramanian, P.; Sevilmis, G.; Globke, B.; Soehnlein, O.; Karshovska, E.; Megens, R.; Heyll, K.; Chun, J.; Saulnier-Blache, J.S.; et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 2011, 13, 592–600. [CrossRef]
10. Chou, C.H.; Lai, S.L.; Ho, C.M.; Lin, W.H.; Chen, C.N.; Lee, P.H.; Peng, F.C.; Kuo, S.H.; Wu, S.Y.; Lai, H.S.Lysophosphatidic acid alters the expression profiles of angiogenic factors, cytokines, and chemokines in mouse liver sinusoidal endothelial cells. PLoS ONE 2015, 10, e0122060. [CrossRef]
11. Kritikou, E.; van Puijvelde, G.H.; van der Heijden, T.; van Santbrink, P.J.; Swart, M.; Schaftenaar, F.H.; Kröner, M.J.; Kuiper, J.; Bot, I. Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient mice. Sci. Rep. 2016, 6, 37585. [CrossRef]
12. Amano, M.; Chihara, K.; Kimura, K.; Fukata, Y.; Nakamura, N.; Matsuura, Y.; Kaibuchi, K. Formation of Actin Stress Fibers and Focal Adhesions Enhanced by Rho-Kinase. Science 1997, 275, 1308–1311. [CrossRef]
13. Kimura, K.; Ito, M.; Amano, M.; Chihara, K.; Fukata, Y.; Nakafuku, M.; Yamamori, B.; Feng, J.; Nakano, T.; Okawa, K.; et al. Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase). Science 1996, 273, 245–248. [CrossRef]
14. Etienne-Manneville, S.; Hall, A. Rho GTPases in cell biology. Nature 2002, 420, 629–635. [CrossRef]
15. Kamiyama, M.; Utsunomiya, K.; Taniguchi, K.; Yokota, T.; Kurata, H.; Tajima, N.; Kondo, K. Contribution of Rho A and Rho Kinase to Platelet-Derived Growth Factor–BB-Induced Proliferation of Vascular Smooth Muscle Cells. J. Atheroscler. Thromb. 2003, 10, 117–123. [CrossRef]
16. Shimokawa, H.; Takeshita, A. Rho-kinase is an important therapeutic target in cardiovascular medicine.Arter. Thromb. Vasc. Biol. 2005, 25, 1767–1775. [CrossRef]
17. Kawanami, D.; Matoba, K.; Kanazawa, Y.; Ishizawa, S.; Yokota, T.; Utsunomiya, K. Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-kappaB signaling pathway activation in vascular endothelial cells. Biochem. Biophys. Res. Commun. 2011, 411, 798–803. [CrossRef]
18. Nakagawa, O.; Fujisawa, K.; Ishizaki, T.; Saito, Y.; Nakao, K.; Narumiya, S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996, 392, 189–193. [CrossRef]
19. Fan, H.; Zingarelli, B.; Harris, V.; Tempel, G.E.; Halushka, P.V.; Cook, J.A. Lysophosphatidic Acid Inhibits Bacterial Endotoxin-Induced Pro-Inflammatory Response: Potential Anti Inflammatory Signaling Pathways. Mol. Med. 2008, 14, 422–428. [CrossRef]
20. Plastira, I.; Bernhart, E.; Goeritzer, M.; Reicher, H.; Kumble, V.B.; Kogelnik, N.; Wintersperger, A.; Hammer, A.; Schlager, S.; Jandl, K.; et al. 1-Oleyl-lysophosphatidic acid (LPA) promotes polarization of BV-2 and primary murine microglia towards an M1-like phenotype. J. Neuroinflammation 2016, 13, 205. [CrossRef]
21. Gosling, J.; Slaymaker, S.; Gu, L.; Tseng, S.; Zlot, C.H.; Young, S.G.; Rollins, B.J.; Charo, I.F. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Investig. 1999, 103, 773–778. [CrossRef]
22. Hwang, S.J.; Ballantyne, C.M.; Sharrett, A.R.; Smith, L.C.; Davis, C.E.; Gotto, A.M., Jr.; Boerwinkle, E. Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases: The Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997, 96, 4219–4225. [CrossRef]
23. Mulero, M.C.; Huang, D.B.; Nguyen, H.T.; Wang, V.Y.; Li, Y.; Biswas, T.; Ghosh, G. DNA-binding affinity and transcriptional activity of the RelA homodimer of nuclear factor κB are not correlated. J. Biol. Chem. 2017, 292, 18821–18830. [CrossRef]
24. Ueda, A.; Ishigatsubo, Y.; Okubo, T.; Yoshimura, T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-κB sites and NF-κB/Rel subunit specificity. J. Biol. Chem. 1997, 272, 31092–31099. [CrossRef]
25. Shimada, H.; Rajagopalan, L.E. Rho-kinase mediates lysophosphatidic acid-induced IL-8 and MCP-1 production via p38 and JNK pathways in human endothelial cells. FEBS Lett. 2010, 584, 2827–2832. [CrossRef]
26. Chen, L.Y.; Zuraw, B.L.; Ye, R.D.; Pan, Z.K. A Rho exchange factor mediates fMet-Leu-Phe-induced NF-kappaB activation in human peripheral blood monocytes. J. Biol. Chem. 2004, 279, 7208–7212. [CrossRef]
27. Fazal, F.; Bijli, K.M.; Minhajuddin, M.; Rein, T.; Finkelstein, J.N.; Rahman, A. Essential role of cofilin-1 in regulating thrombin-induced RelA/p65 nuclear translocation and intercellular adhesion molecule 1 (ICAM-1) expression in endothelial cells. J. Biol. Chem. 2009, 284, 21047–21056. [CrossRef]
28. Meyer-Schwesinger, C.; Dehde, S.; von Ruffer, C.; Gatzemeier, S.; Klug, P.; Wenzel, U.O.; Stahl, R.A.; Thaiss, F.; Meyer, T.N. Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-kappaB p65 signaling. Am. J. Physiol. Ren. Physiol. 2009, 296, F1088–F1099. [CrossRef]
29. Brown, K.; Gerstberger, S.; Carlson, L.; Franzoso, G.; Siebenlist, U. Control of IκBα Proteolysis by Site-Specific,Signal-induced Phosphorylation. Science 1995, 267, 1485–1488. [CrossRef]
30. Traenckner, E.B.; Pahl, H.L.; Henkel, T.; Schmidt, K.N.; Wilk, S.; Baeuerle, P.A. Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J. 1995, 14, 2876–2883. [CrossRef]
31. Schweitzer, K.; Bozko, P.M.; Dubiel, W.; Naumann, M. CSN controls NF-κB by deubiquitinylation of IκBα.EMBO J. 2007, 26, 1532–1541. [CrossRef]
32. Panday, A.; Inda, M.E.; Bagam, P.; Sahoo, M.K.; Osorio, D.; Batra, S. Transcription Factor NF-kappaB: An Update on Intervention Strategies. Arch. Immunol. Exp. 2016, 64, 463–483. [CrossRef]
33. Anwar, K.N.; Fazal, F.; Malik, A.B.; Rahman, A. RhoA/Rho-Associated Kinase Pathway Selectively Regulates Thrombin-Induced Intercellular Adhesion Molecule-1 Expression in Endothelial Cells via Activation of IκB Kinase and Phosphorylation of RelA/p65. J. Immunol. 2004, 173, 6965–6972. [CrossRef]
34. Matoba, K.; Kawanami, D.; Tsukamoto, M.; Kinoshita, J.; Ito, T.; Ishizawa, S.; Kanazawa, Y.; Yokota, T.; Murai, N.; Matsufuji, S.; Utsunomiya, K. Rho-kinase regulation of TNF-α-induced nuclear translocation of NF-κB RelA/p65 and M-CSF expression via p38 MAPK in mesangial cells. Am. J. Physiol. Ren. Physiol. 2014, 307, F571–F580. [CrossRef]
35. Antoniellis Silveila, A.A.; Dominical, V.M.; Morelli Vital, D.; Alves Ferreira, W., Jr.; Trindade Maranhao Costa, F.; Werneck, C.C.; Ferreira Costa, F.; Conran, N. Attenuation of TNF-induced neutrophil adhesion by simvastatin is associated with the inhibition of Rho-GTPase activity, p50 activity and morphological changes. Int. Immunopharamacol. 2018, 58, 160–165. [CrossRef]
36. Pelosi, M.; Marampon, F.; Zani, B.M.; Prudente, S.; Perlas, E.; Caputo, V.; Cianetti, L.; Berno, V.; Narumiya, S.; Kang, S.W.; et al. ROCK2 and its alternatively spliced isoform ROCK2m positively control the maturation of the myogenic program. Mol. Cell. Biol. 2007, 17, 6163–6176. [CrossRef]
37. Beckers, C.M.; Knezevic, N.; Valent, E.T.; Tauseef, M.; Krishnan, R.; Rajendran, K.; Hardin, C.C.; Aman, J.; van Bezu, J.; Sweetnam, P.; et al. ROCK2 primes the endothelium for vascular hyperpermeability responses by raising baseline junctional tension. Vasc. Pharmacol. 2015, 70, 45–54. [CrossRef]
38. Sawada, N.; Liao, J.K. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid. Redox Signal. 2014, 20, 1251–1267. [CrossRef]
39. Shimizu, T.; Fukumoto, Y.; Tanaka, S.; Satoh, K.; Ikeda, S.; Shimokawa, H. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Arter. Thromb. Vasc. Biol. 2013, 33, 2780–2791. [CrossRef]
40. Satoh, S.; Takayasu, M.; Kawasaki, K.; Ikegaki, I.; Hitomi, A.; Yano, K.; Shibuya, M.; Asano, T. Antivasospastic Effects of Hydroxyfasudil, a Rho-Kinase Inhibitor, After Subarachnoid Hemorrhage. J. Pharm. Sci. 2012, 118, 92–98. [CrossRef]
41. Feng, Y.; LoGrasso, P.V.; Defert, O.; Li, R. Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.J. Med. Chem. 2016, 59, 2269–2300. [CrossRef] [PubMed]
42. Garnock-Jones, K.P. Ripasudil: First global approval. Drugs 2014, 74, 2211–2215. [CrossRef] [PubMed]
43. Lee, J.H.; Zheng, Y.; von Bornstadt, D.; Wei, Y.; Balcioglu, A.; Daneshmand, A.; Yalcin, N.; Yu, E.; Herisson, F.; Atalay, Y.B.; et al. Selective ROCK2 Inhibition In Focal Cerebral Ischemia. Ann. Clin. Transl. Neurol. 2014, 1, 2–14. [PubMed]
44. Zanin-Zhorov, A.; Weiss, J.M.; Nyuydzefe, M.S.; Chen, W.; Scher, J.U.; Mo, R.; Depoil, D.; Rao, N.; Liu, B.; Wei, J.; et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc. Natl. Acad. Sci. USA 2014, 111, 16814–16819. [CrossRef] [PubMed]
45. Flynn, R.; Paz, K.; Du, J.; Reichenbach, D.K.; Taylor, P.A.; Panoskaltsis-Mortari, A.; Vulic, A.; Luznik, L.; MacDonald, K.K.; Hill, G.R.; et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 2016, 127, 2144–2154. [CrossRef] [PubMed]
46. Zanin-Zhorov, A.; Weiss, J.M.; Trzeciak, A.; Chen, W.; Zhang, J.; Nyuydzefe, M.S.; Arencibia, C.; Polimera, S.; Schueller, O.; Fuentes-Duculan, J.; et al. Cutting edge: Selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10. J. Immunol. 2017, 198, 3809–3814. [CrossRef] [PubMed]
47. Subramanian, P.; Karshovska, E.; Reinhard, P.; Megens, R.T.; Zhou, Z.; Akhtar, S.; Schumann, U.; Li, X.; van Zandvoort, M.; Ludin, C.; et al. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ. Res. 2010, 107, 96–105. [CrossRef] [PubMed]
48. Zhao, C.; Sardella, A.; Chun, J.; Poubelle, P.E.; Fernandes, M.J.; Bourgoin, S.G. TNF-alpha promotes LPA1- and LPA3-mediated recruitment of leukocytes in vivo through CXCR2 ligand chemokines. J. Lipid Res. 2011, 52, 1307–1318. [CrossRef]
49. Miyata, K.; Shimokawa, H.; Kandabashi, T.; Higo, T.; Morishige, K.; Eto, Y.; Egashira, K.; Kaibuchi, K.; Takeshita, A. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler. Hromb. Vasc. Biol. 2000, 20, 2351–2358. [CrossRef]
論文の公開元へ
